Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Top Cited Papers
- 10 May 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 5 (4), 262-270
- https://doi.org/10.1038/sj.tpj.6500313
Abstract
No abstract availableKeywords
This publication has 44 references indexed in Scilit:
- Intracranial traumatic and non-traumatic haemorrhagic complications of warfarin treatmentActa Neurologica Scandinavica, 2009
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarinClinical Pharmacology & Therapeutics, 2004
- Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factorsThe Pharmacogenomics Journal, 2003
- Pharmacogenetics and Anticoagulant TherapyJournal of Thrombosis and Thrombolysis, 2003
- Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarinThe Pharmacogenomics Journal, 2003
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearanceClinical Pharmacology & Therapeutics, 2002
- Interindividual variability in sensitivity to warfarin-Nature or nurture?Clinical Pharmacology & Therapeutics, 2001
- Yoga in treatment of carpal-tunnel syndromeThe Lancet, 1999
- Anticoagulant-related bleeding: Clinical epidemiology, prediction, and preventionThe American Journal of Medicine, 1993